k) Provisions, Contingent Liabilities and
Contingent Assets

A provision is recognized when the Company
has a present obligation (legal or constructive)
as a result of a past event and it is probable that
an outflow of resources embodying economic
benefits will be required to settle the obligation,
in respect of which a reliable estimate can be
made. These are reviewed at each balance
sheet date and adjusted to reflect the current
management estimates.

Contingent Liabilities are disclosed in respect
of possible obligations that arise from past
events but their existence is confirmed by the
occurrence or non-occurrence of one or more
uncertain future events not wholly within the
control of the Company.

A contingent asset is a possible asset that
arises from past events and whose existence
will be confirmed only by the occurrence or non¬
occurrence of one or more uncertain future
events not wholly within the control of the
entity. Contingent Assets are not recognized till
the realization is virtually certain. However the
same are disclosed in the financial statements
where an inflow of economic benefit is probable.
Contingent liability and contingent asset are
reviewed at each balance sheet date.

l) Revenue Recognition

Revenue comprises of revenue from providing
healthcare services such as health checkup and
laboratory services. Pathology service is the only
principal activity and reportable segment from
which the Company generates its revenue.

Revenue is recognised at an amount that reflects
the consideration to which the Company expects
to be entitled in exchange for transferring the
goods or services to a customer i.e. on transfer
of control of the service to the customer.
Revenue from rendering of services is net of
indirect taxes, reversals and discounts.

Revenue is recognised once the testing samples
are processed for requisitioned test, to the
extent that it is probable that the economic
benefits will flow to the Company and revenue
can be reliably measured.

Revenue is measured based on the consideration
specified in a contract with a customer. Revenue
is recognised at a point in time when the
Company satisfies performance obligations
by transferring the promised services to its
customers. Generally, each test represents
a separate performance obligation for which
revenue is recognised when the test report is
generated i.e. when the performance obligation
is satisfied. For allocating the transaction price,
the Company has measured the revenue in
respect of each performance obligation of a

contract at its relative standalone selling price.
The price that is regularly charged for a test
when registered separately is the best evidence
of its standalone selling price

Contract liabilities

A contract liability is the obligation to transfer
services to a customer for which the Company
has received consideration from the customer.
If a customer pays consideration before the
Company transfers services to the customer, a
contract liability is recognised when the payment
is made. Contract liabilities are recognised as
revenue when the Company performs under
the contract.

m) Recognition of Interest income and
Dividend income

Interest income

For all financial instruments measured at
amortized cost, interest income is recorded
using the effective interest rate (EIR). EIR is
the rate which exactly discounts the estimated
future cash receipts over the expected life of
the financial instrument to the gross carrying
amount of the financial asset. When calculating
the EIR the Company estimates the expected
cash flows by considering all the contractual
terms of the financial instrument (for example,
prepayments, extensions, call and similar
options); expected credit losses are considered
if the credit risk on that financial instrument has
increased significantly since initial recognition

Dividend income

Dividends are recognized in statement of profit
and loss on the date on which the Company's
right to receive payment is established.

n) Employee Benefits

(i) Short-term Employee benefits

Liabilities for wages and
salaries,compensated absences, bonus and
ex gratia including non-monetary benefits
that are expected to be settled wholly
within twelve months after the end of the
year in which the employees render the
related service are classified as short term
employee benefits and are recognized as
an expense and measured on undiscounted
basis in the Statement of Profit and Loss as
the related service is provided.

A liability is recognized for the amount
expected to be paid if the Company has a
present legal or constructive obligation to
pay this amount as a result of past service
provided by the employee and the obligation
can be estimated reliably.

(ii) Share-based payments

The cost of equity settled transactions is
determined by the fair value at the grant
date which is based on the Black Scholes
model. The grant date fair value of options
granted to employees is recognized as an
employee expense, with a corresponding
increase in equity under "Employee Stock
Options Reserve", over the period that the
employees become unconditionally entitled
to the options.

The expense so determined is recognised
over the requisite vesting period, which is
the period over which all of the specified
vesting conditions are to be satisfied. As at
each reporting date, the Company revises
its estimates of the number of options that
are expected to vest, if required.

When the terms of an equity-settled
award are modified, in addition to the
expense pertaining to the original award,
an incremental expense is recognised for
any modification that results in additional
fair value, or is otherwise beneficial to
the employee as measured at the date
of modification.

(iii) Post-Employment Benefits
Defined Contribution Plans:

A defined contribution plan is a post¬
employment benefit plan under which a
Company pays specified contributions to
a separate entity and has no obligation
to pay any further amounts. The Company
makes contribution to provident fund in
accordance with Employees Provident
Fund and Miscellaneous Provisions Act,
1952 and Employee State Insurance.
Contribution paid or payable in respect of
defined contribution plan is recognized as
an expense in the year in which services
are rendered by the employee. Prepaid
contributions are recognised as an asset
to the extent that cash refund or reduction
in future payments is available.

Defined Benefit Plans:

The Company's gratuity benefit scheme is a
defined benefit plan. The liability recognised
in the balance sheet in respect of gratuity
is the present value of the defined benefit/
obligation at the balance sheet date less
the fair value of plan assets, together with
adjustments for unrecognised acturial gain
losses and past service costs. The defined
benefit/obligation are calculated at balance
sheet date by an independent actuary using
the projected unit credit method.

When the calculation results in potential
asset for the company ,the recognised
asset is limited to the present value of
economic benefits available in the form
of any future refunds from the plan or
reduction in the future contribution to the
plan(the asset ceiling). Remeasurements
of the net defined obligations/liability
which compromise actuarial gains and
losses ,the return on plan assets (excluding
interest) and the effect of asset ceiling (if
any excluding interest) are recognised
immediately in OCI.

When the benefits of a plan are changed
or when a plan is curtailed the resulting
change in benefit that relates to past
service (Past service cost or past service
gain) or the gain or loss on curtailment is
recognised immediately in profit and losss.
The group recognises gains and losses on
the settlement of a defined benefit plan
when the settlement occours.

Compensated absences:

The Company follows calendar year (January
to December) for leave management. As
per policy, Privilege Leave is accrued on 1^st
of January for the entire year. Leaves can
be accumulated upto 30 days and can be
encashed at the time of exit along with full
and final settelment. All other leaves get
lapsed at the end of December.

o) Leases

At inception of a contract, the Company
assesses whether a contract is, or contains, a
lease. A contract is, or contains, a lease if the
contract conveys the right to control the use
of an identified asset for a period of time in
exchange for consideration.

As a lessee

Leases are recognised as a right-of-use asset
and a corresponding liability at the date at
which the leased asset is available for use by
the Company. Contracts may contain both lease
and non-lease components. The Company
allocates the consideration in the contract to
the lease and non-lease components based on
their relative stand-alone prices. However, for
leases of real estate for which the Company is a
lessee, it has elected not to separate lease and
non-lease components and instead accounts for
these as a single lease component.

Assets and liabilities arising from a lease are
initially measured on a present value basis.
Lease liabilities include the net present value of
the following lease payments:

- Fixed payments (including in-substance fixed
payments), less incentives receivables

- Variable lease payments that are based on
an index or a rate, initially measured using
the index or rate at the commencement date

- amount expected to be payable by the
company under residual value guarantees

- the exercise price of a purchase option if the
Company is reasonably certain to exercise
that option, and

- Payments of penalties for terminating the
lease, if the lease term reflects the Company
exercising that option.

The lease liability is measured at amortised cost
using effective interest method. It is remeasured
when there is change in assessment of
whether it will exercise a purchase, extension
or termination option or if there is a revised in¬
substance fixed lease payment.

When the lease liability is remeasured in this
way, a corresponding adjustment is made to the
carrying amount of the right of use asset, or is
recorded in profit or loss if the carrying amount
of the right of use asset has been reduced
to zero.

Lease payments to be made under reasonably
certain extension options are also included
in the measurement of the liability. The lease
payments are discounted using the interest

rate implicit in the lease. If that rate cannot
be readily determined, which is generally the
case for leases in the Company, the lessee's
incremental borrowing rate is used, being the
rate that the individual lessee would have to
pay to borrow the funds necessary to obtain an
asset of similar value to the right-of-use asset
in a similar economic environment with similar
terms, security and conditions.

To determine the incremental borrowing rate,
the Company:

• where possible, uses recent third-party
financing received as a starting point, adjusted
to reflect changes in financing conditions
since third party financing was received

• uses a build-up approach that starts with a
risk-free interest rate adjusted for credit risk
for leases held, which does not have recent
third party financing, and makes adjustments
specific to the lease, e.g. term, country,
currency and security.

Variable lease payments that depend on sales
are recognised in profit or loss in the period
in which the condition that triggers those
payments occurs.

The right of use asset is initially measured at
cost, which comprises the initial amount of the
lease liability adjusted for any lease payments
made at or before the commencement date,
plus any initial direct costs incurred and an
estimate of costs to dismantle and remove the
underlying asset or to restore the underlying
asset or the site on which it is located, less
any incentives received.They are subsequently
measured at cost or accumulated depreciation
and impairment losses

Right-of-use assets are generally depreciated
over the shorter of the asset's useful life and the
lease term on a straight-line basis. If the Company
is reasonably certain to exercise a purchase
option, the right-of-use asset is depreciated
over the underlying asset's useful life.

In addition, the right of use of assets is
periodically reduced by impairment losses if any
and adjusted for certain remeasurements of the
lease liability.

Payments associated with short-term leases of
equipment and all leases of low-value assets
are recognised on a straight-line basis as an
expense in profit or loss. Short-term leases are
leases with a lease term of 12 months or less.

The lease liability is presented as a separate line
in the statement of financial position. The lease
liability is subsequently measured by increasing
the carrying amount to reflect interest on the
lease liability (using the effective interest
method) and by reducing the carrying amount to
reflect the lease payments made. The Company
remeasures the lease liability (and makes a
corresponding adjustment to the related right-
of-use asset) whenever

• the lease term has changed or there is a
change in the assessment of exercise of
a purchase option, in which case the lease
liability is remeasured by discounting the
revised lease payments using a revised
discount rate.

• the lease payments change due to changes
in an index or rate or a change in expected
payment under a guaranteed residual value, in
which cases the lease liability is remeasured
by discounting the revised lease payments
using the initial discount rate (unless the
lease payments change is due to a change
in a floating interest rate, in which case a
revised discount rate is used).

• a lease contract is modified and the lease
modification is not accounted for as a
separate lease, in which case the lease liability
is remeasured by discounting the revised
lease payments using a revised discount rate.

p) Income-tax

Income tax expense comprises current tax
and deferred tax. It is recognized in statement
of profit and loss except to the extent that it
relates to items recognized directly in equity or
in Other Comprehensive Income, in which case,
the tax is also recognized directly in equity or
other comprehensive income, respectively.

Current Tax

Current tax comprises the expected tax payable
or recoverable on the taxable profit or loss
for the year and any adjustment to the tax
payable or recoverable in respect of previous
years. It is measured using tax rates enacted

or substantively enacted by the end of the
reporting period.The amount of current tax
payable or receivable is the best estimate of th
tax amount expected to be paid or recived that
reflects uncertainty related to income taxes,
if any.

• Current tax assets and liabilities are offset
only if the Company has a legally enforceable
right to set off the recognized amounts; and

• intends either to settle on a net basis,
or to realize the asset and settle the
liability simultaneously

• Current tax assets and liabilities are offset
only if there is alegally enforceable right
to setoff the recognised amounts and it
is intended to realise the asset and settle
liability on a net basis.

Deferred Tax

Deferred tax is recognised in respect of
temporary differences between the carrying
amounts of assets and liabilities for financial
reporting purposes and the corresponding
amounts used for taxation purposes. Deferred
tax is also recognised in respect of carried
forward tax losses and tax credits. Deferred tax
is not recognised for:

• temporary differences on the initial recognition
of assets or liabilities in a transaction that:

- is not a business combination; and

- at the time of the transaction (i) affects
neither accounting nor taxable profit or
loss and (ii) does not give rise to equal
taxable and deductible temporary
differences;

• temporary differences related to investments
in subsidiaries, associates and joint
arrangements to the extent that the Company
is able to control the timing of the reversal of
the temporary differences and it is probable
that they will not reverse in the foreseeable
future; and

• taxable temporary differences arising on the
initial recognition of goodwill.

Deferred tax assets are recognised for unused
tax losses, unused tax credits and deductible

temporary differences to the extent that it
is probable that future taxable profits will
be available against which they can be used.
Future taxable profits are determined based
on the reversal of relevant taxable temporary
differences. If the amount of taxable temporary
differences is insufficient to recognise a
deferred tax asset in full, then future taxable
profits, adjusted for reversals of existing
temporary differences, are considered, based on
the business plans for individual subsidiaries in
the Company. Deferred tax assets are reviewed
at each reporting date and are reduced to
the extent that it is no longer probable that
the related tax benefit will be realised; such
reductions are reversed when the probability of
future taxable profits improves.

Deferred tax is measured at the tax rates
that are expected to apply to the period when
the asset is realised or the liability is settled,
based on the laws that have been enacted or
substantively enacted by the reporting date.

The measurement of deferred tax reflects the tax
consequences that would follow from the manner
in which the Company expects, at the reporting
date, to recover or settle the carrying amount
of its assets and liabilities. For this purpose,
the carrying amount of investment property is
presumed to be recovered through sale.

Deferred tax assets and liabilities are offset
if there is a legally enforceable right to offset
current tax liabilities and assets, and they
relate to income taxes levied by the same tax
authority on the same taxable entity, or on
different tax entities, but they intend to settle
current tax liabilities and assets on a net
basis or their tax assets and liabilities will be
realised simultaneously.

The measurement of deferred tax assets and
liabilities reflects the tax consequences that
would follow from the manner in which the
Company expects, at the reporting date, to
recover or settle the carrying amount of its
assets and liabilities.

Deferred tax assets and liabilities are offset
only if:

i) the entity has a legally enforceable right to
set off current tax assets against current
tax liabilities; and

ii) the deferred tax assets and the deferred
tax liabilities relate to income taxes levied
by the same taxation authority on the same
taxable entity.

Uncertain tax provision

Management periodically evaluates positions
taken in the tax returns with respect to situations
in which applicable tax regulations are subject to
interpretation and establishes provisions where
appropriate. The provision is estimated based on
one of two methods, the expected value method
(the sum of the probability weighted amounts
in a range of possible outcomes) or the single
most likely amount method, depending on which
is expected to better predict the resolution of
the uncertainty.

q) Foreign currency transactions

Functional and Presentation currency

The Company's financial statements are
prepared in Indian Rupees (INR) which is also the
Company's functional currency.

Transactions and balances

Foreign currency transactions are recorded on
initial recognition in the functional currency using
the exchange rate at the date of the transaction.

Monetary assets and liabilities denominated
in foreign currencies are translated into the
functional currency at the exchange rate at the
reporting date. Non-monetary items that are
measured based on historical cost in a foreign
currency are translated using the exchange
rate at the date of the initial transaction. Non¬
monetary items that are measured at fair
value in a foreign currency are translated using
the exchange rate at the date the fair value
is determined.

Exchange differences arising on the settlement
or translation of monetary items are recognized
in statement of profit or loss in the year in which
they arise.

r) Dividend

The Company recognises a liability for any
dividend declared but not distributed at the end
of the reporting period, when the distribution
is authorized by the shareholders in AGM and
the distribution is no longer at the discretion
of the Company on or before the end of the
reporting period.

Interim dividends are recognized as a liability
in the period in which they are approved by the
Board of Directors. They are accounted for in the
Statement of Changes in Equity and adjusted
against retained earnings. No provision is
made for dividends declared after the reporting
date unless approved before the end of the
reporting period.

s) Earnings per share:

Basic Earnings per share is calculated by dividing
the profit or loss for the year attributable to the
equity shareholders by the weighted average
number of equity shares outstanding during
the year.

For the purpose of calculating diluted earnings
per share, the profit or loss for the period
attributable to the equity shareholders and
the weighted average number of equity shares
outstanding during the period is adjusted to
take into account:

• The after income tax effect of interest and
other financing costs associated with dilutive
potential equity shares, and

• Weighted average number of additional equity
shares that would have been outstanding
assuming the conversion of all dilutive
potential equity shares.

t) Segment Reporting

Operating segments are defined as components
of an enterprise for which discrete financial
information is available that is evaluated
regularly by the chief operating decision maker,
in deciding how to allocate resources and
assessing performance. The Company's chief
operating decision maker is the Managing
Director of the Company.

Segment revenue, segment expenses, segment
assets and segment liabilities have been
identified to segments on the basis of their
relationship to the operating activities of the
segment. Inter segment revenue is accounted
on the basis of transactions which are primarily
determined based on market / fair value factors.
Revenue, expenses, assets and liabilities which
relate to the Company as a whole and are not
allocable to segments on a reasonable basis
have been included under ""unallocated revenue
/ expenses / assets / liabilities"".

Based on the nature of the business and line of
products/ services, there is only one reportable
segment - Pathology service.

u) Discontinued operations

A discontinued operation is a component of the
Group's business, the operations and cash flows
of which can be clearly distinguished from the
rest of the Group and which:

• represents a separate major line of business
or geographic area of operations;

• is part of a single co-ordinated plan to
dispose of a separate major line of business
or geographic area of operations; or

• is a subsidiary acquired exclusively with a
view to resale.

Classification as a discontinued operation
occurs at the earlier of disposal or when the
operation meets the criteria to be classified as
held-for-sale.

When an operation is classified as a discontinued
operation, the comparative statement of profit
and loss is re-presented as if the operation
had been discontinued from the start of the
comparative year.

v) Asset held for Sale

Non-current assets, or disposal groups
comprising assets and liabilities, are classified
as held for sale if it is highly probable that they
will be recovered primarily through sale rather
than through continuing use.

Such assets, or disposal groups, are generally
measured at the lower of their carrying amount
and fair value less costs to sell.

Any impairment loss on a disposal group is
allocated first to goodwill, and then to the
remaining assets and liabilities on a pro rata
basis, except that no loss is allocated to
inventories, financial assets, deferred tax assets,
employee benefit assets, or biological assets,
which continue to be measured in accordance
with the Group's other accounting policies.
Impairment losses on initial classification as held
for sale or held for distribution and subsequent
gains and losses on remeasurement are
recognised in profit or loss.

Once classified as held for sale, intangible
assets, property, plant and equipment and
investment properties are no longer amortised
or depreciated, and equity-accounted investee
is no longer equity accounted.

Non-current assets classified as held-for-sale
and the assets of a disposal group classified as
held for sale are presented separately from the
other assets in the balance sheet. The liabilities
of a disposal group classified as held for sale are
presented separately from other liabilities in the
balance sheet.

w) Share Capital

Equity shares

Incremental costs directly attributable to the
issue of equity shares are recognised as a
deduction from equity. Income tax relating to
transaction costs of an equity transaction is
accounted for in accordance with Ind AS 12

x) Recent Indian Accounting Standards (Ind
AS)

The Ministry of Corporate Affairs vide notification
dated 7 May 2025 and 13 August 2025 notified
the Companies (Indian Accounting Standards)
Amendment Rules, 2025 and Companies (Indian
Accounting Standards) Second Amendment
Rules, 2025, respectively, which amended certain
accounting standards (see below), and are
effective for annual reporting periods beginning
on or after 1 April 2025

Classification of Liabilities as Current or
Non-current and Non-current Liabilities with
Covenants - Amendments to Ind AS 1

As a result of the adoption of the amendments
to Ind AS 1, the company changed its accounting
policy for the classification of borrowings:

Borrowings are classified as current liabilities
unless, at the end of the reporting period, the
company has a right to defer settlement of
the liability for at least 12 months after the
reporting period.

Covenants that the company is required
to comply with, on or before the end of the
reporting period, are considered in classifying
loan arrangements with covenants as current
or non-current. Covenants that the company
is required to comply with after the reporting
period do not affect the classification.

This new policy did not result in a change in
the classification of Metropolis Healthcare
Limited's borrowings. The Company did not
make retrospective adjustments as a result of
adopting the amendments to Ind AS 1.

Supplier Finance Arrangements - Amendments
to Ind AS 7 and Ind AS 107

As a result of the adoption of the amendments
to Ind AS 7 and Ind AS 107,the Company does not
expect material impact of these amendments in
its financial statements.

International Tax Reform - Pillar Two Model
Rules - Amendments to Ind AS 12

Metropolis Healthcare Limited is not within
the scope of the OECD Pillar Two Model Rules,
as Pillar Two legislation has not yet been
enacted in any of the jurisdictions in which the
company operates.

Lack of Exchangeability - Amendments to Ind
AS 21

The amended Ind AS 21 have added requirements
to help entities to determine whether a currency
is exchangeable into another currency, and the
spot exchange rate to use where it is not. These
amendments did not have any material impact
on the amounts recognised in current periods
and are not expected to significantly affect the
future periods.

Recent Indian Accounting Standards (Ind AS)
issued not yet effective
Classification of Liabilities as Current or
Non-current and Non-current Liabilities with
Covenants - Amendments to Ind AS 1

This amendment also includes specific
provisions that will take effect for reporting
periods beginning on or after 1 April 2026, as
outlined below.

Under the existing Ind AS 1, where there is a
breach of a material provision of a long-term
loan arrangement on or before the end of the
reporting period with the effect that the liability
becomes payable on demand on the reporting
date, the entity does not classify the liability as
current, if the lender agreed, after the reporting
period and before the approval of the financial
statements for issue, not to demand payment
as a consequence of the breach.

However, the amended requirements stipulate
that entities will no longer be permitted to
consider lender waivers that are granted after
the reporting date but before the financial
statements are approved for the purpose
of classification of loans. This amendment
is required to be applied retrospectively in
accordance with Ind AS 8.

Metropolis Healthcare Limited does not expect
this amendment to have an impact on its
operations or financial statements.

The recoverable amount of a CGU is determined using income approach under the fair value less cost of disposal
method. The value in use is estimated using discounted cash flows over a period of 5 years. We believe 5 years to be
most appropriate time scale over which to review and consider annual performance before applying a fix terminal value
multiple to year end cash flow.

Operating margins and growth rates for the five year cash flow projections have been estimated based on past
experience and after considering the financial budgets/ forecasts approved by management. Other key assumptions
used in the estimation of the recoverable amount are set out below. The values assigned to the key assumptions
represent management's assessment of future trends and have been based on historical data from both external and
internal sources.

(e) Terms/rights attached to equity shares

The Company has only one class of Equity shares having a par value of '2 per share. Each holder of equity share is
entitled to one vote per share. The Company declares and pays dividend in Indian Rupees. The dividend, if proposed
by the Board of Directors, will be subject to the approval of the shareholders in the ensuing Annual General Meeting
except interim dividend.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets
of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number
of equity shares held by the shareholders.

(f) The Company has issued and allotted 15,54,95,826 Bonus Equity Shares in the ratio of 3:1, i.e., Three (3) new fully
paid-up Equity Shares of face value of INR 2/- each for every One (1) existing fully paid-up Equity Share of face
value of INR 2/- each. The Board of Directors at their meeting held on 4 February, 2026 approved issuance of bonus
shares, which was approved by the shareholders on 08 March 2026.

Securities Premium

The amount received in excess of face value of the equity shares is recognised in Securities Premium. It can be used
to issue bonus shares, to purchase of its own shares, to provide for premium on redemption of shares or debentures,
write-off equity related expenses like underwriting costs, etc.

Capital redemption reserve

As per Companies Act, 2013, capital redemption reserve is created when company purchases its own shares out of free
reserves or securities premium. A sum equal to the nominal value of the shares so purchased is transferred to capital
redemption reserve. The reserve is to be utilised in accordance with the provisions of section 69 of the Companies
Act, 2013.

General Reserve

General Reserve is free reserve which is created by transferring funds from retained earnings to meet future obligations
or purposes.

Share application money pending allotment

Share Application Money Pending Allotment represents application money received on account of Employees Stock
Option Scheme.

Employee stock options reserve

The Company has established equity settled share based payment plan for certain categories of employees. (Refer
Note 45)

Retained Earnings

Retained earnings are the profits that the Company has earned till date, less any transfers to general reserve, dividends
or other distributions paid to shareholders. Retained Earnings is a free reserve available to the Company.

Re-measurement gain/ (loss) on defined benefit plans (net of taxes)

The Company has elected to recognise changes in the value of certain liabilities toward employee compensation in
Other Comprehensive Income. These changes are accumulated within re-measurement gain/ (loss) on defined benefit
plan reserve within equity.

36 Earnings per share (EPS)

Basic EPS is calculated by dividing the net profit for the year attributable to equity holders by the weighted average
number of Equity shares outstanding during the year.

Diluted EPS amounts are calculated by dividing the profit attributable to equity holders (after adjusting profit impact
of dilutive potential equity shares, if any) by the aggregate of weighted average number of Equity shares outstanding
during the year and the weighted average number of Equity shares that would be issued on conversion of all the dilutive
potential Equity shares into Equity shares.

Financial instruments with fixed and variable interest rates are evaluated by the Company based on parameters
such as interest rates and individual creditworthiness of the counterparty. Based on this evaluation, allowances
are taken to account for expected losses of these receivables. Accordingly, fair value of such instruments is not
materially different from their carrying amounts.

B. Fair value hierarchy

Ind AS 107, 'Financial Instrument - Disclosure' requires classification of the valuation method of financial instruments
measured at fair value in the Balance Sheet, using a three level fair-value-hierarchy (which reflects the significance
of inputs used in the measurements). The hierarchy gives the highest priority to un-adjusted quoted prices in active
markets for identical assets or liabilities (Level 1 measurements) and lowest priority to un-observable inputs (Level
3 measurements). The three levels of the fair-value-hierarchy under Ind AS 107 are described below:

Level 1: Level 1 hierarchy includes financial instruments measured using quoted prices.

Level 2: The fair value of financial instruments that are not traded in an active market is determined using valuation
techniques which maximise the use of observable market data and rely as little as possible on entity specific
estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included
in level 2.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included
in this level. This is the case for unlisted equity securities included in level 3.

Financial instruments measured at fair value

The following table shows the valuation techniques used in measuring Level 1 and Level 3 fair values for financial
instruments measured at fair value in the balance sheet as well as the significant unobservable inputs used.

C. Financial risk management
Risk management framework

The Company's board of directors has overall responsibility for the establishment and oversight of the company's
risk management framework. The board of directors has established the risk management committee, which is
responsible for developing and monitoring the company's risk management policies. The committee reports regularly
to the board of directors on its activities.

The company's risk management policies are established to identify and analyse the risks faced by the company, to
set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and
systems are reviewed regularly to reflect changes in market conditions and the company's activities. The company,
through its training and management standards and procedures, aims to maintain a disciplined and constructive
control environment in which all employees understand their roles and obligations.

The company audit committee oversees how management monitors compliance with the company's risk
management policies and procedures and reviews the adequacy of the risk management framework in relation to

Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails
to meet its contractual obligations, and arises principally from the Company's trade and other receivables and cash
and cash equivalents. The maximum exposure to credit risk in case of all the financial instruments covered below
is restricted to their respective carrying amount.

a. Trade receivables and other receivables

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer.
Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the
creditworthiness of customers to which the Company grants credit terms in the normal course of business.
The Company establishes an allowance for doubtful debts and impairment that represents its estimate of
incurred losses in respect of trade and other receivables and investments.

The Company does not have any significant concentration of credit risk. Further, company has no customer
(31 March 2025- Nil) which accounts for 10% or more of the total trade receivables at each reporting date.

Trade receivables are generally on terms of 30 to 90 days.

The Company has used a practical expedient by computing the expected credit loss allowance for trade
receivables based on a provision matrix.

b. Cash and cash equivalents and Other bank balances

The Company held cash and cash equivalents and other bank deposits as at 31 March 2026'2,078.85 lakhs
(31 March 2025'2,587.48 lakhs). The cash and cash equivalents and other bank balances are held with banks
with good credit ratings.

c. Investments

The Company limits its exposure to credit risk by generally investing in liquid securities and only with
counterparties that have a good credit rating. The Company does not expect any losses from non-performance
by these counter-parties, and does not have any significant concentration of exposures to specific industry
sectors or specific country risks.

d. Loans and advances

Loans and advances mainly consist security deposit and advances to related parties.

The security deposit pertains to rent deposit given to lessors. The Company does not expect any losses from
non-performance by these counter-parties.

The loans and advances given majorly pertains to subsidiaries. The parties have been generally regular in
making payments and hence the Company does not expect significant impairment losses on its current profile
of outstanding advances. The advances which have defaulted in the past is mainly on account of uncontrollable
adverse local market conditions which has diluted parties' credit worthiness.

Market risk:

Market risk is the risk that changes in market prices - such as foreign exchange rates, interest rates and equity
prices - will affect the Company's income or the value of its holdings of financial instruments. The Company is
exposed to market risk primarily related to foreign exchange rate risk and interest rate risk. The objective of market
risk management is to avoid excessive exposure in foreign currency revenues and costs.

a. Currency risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because
of changes in foreign exchange rates. The Company has foreign currency trade payables and receivables and
is therefore exposed to foreign exchange risk.

Liquidity risk:

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its
financial liabilities. Prudent liquidity risk management implies maintaining sufficient cash and marketable securities,
the availability of funding through an adequate amount of committed credit facilities. The Company's approach
to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when
they are due, under both normal and stressed conditions.

Maturities of financial liabilities

The table below analyses the Company's financial liabilities (undiscounted basis) into relevant maturity groupings
based on their contractual maturities:

The outflows disclosed in the above table represent the total contractual undiscounted cash flows and total interest
payable on borrowings, if any.

b. Interest rate risk

Interest rate risk can be either fair value interest rate risk or cash flow interest rate risk. Fair value interest
rate risk is the risk of changes in fair values of fixed interest bearing investments because of fluctuations in
the interest rates. Cash flow interest rate risk is the risk that the future cash flows of floating interest bearing
investments will fluctuate because of fluctuations in the interest rates.

The Company does not account for any fixed-rate financial assets or financial liabilities at fair value through
profit or loss. Therefore, a change in interest rates at the reporting date would not affect profit or loss.

(D) Capital management

The objective of the Company's capital management is to ensure that it maintains an efficient capital structure
and healthy capital ratios to support its business and maximize shareholder value.

The Company has equity capital and other reserves attributable to the equity shareholders, as the only source of
capital and the company has insignificant interest bearing borrowings/ debts as on the reporting date. Hence, the
Company is not subject to any externally imposed capital requirements.

The Company's capital management is driven by Company's policy to maintain a sound capital base to support
the continued development of its business. The Board of Directors seeks to maintain a prudent balance between
different components of the Company's capital. The Management monitors the capital structure and the net
financial debt at individual currency level. Net financial debt is defined as current and non-current financial liabilities
less cash and cash equivalents and short-term investments.

The Company monitors capital using a ratio of 'adjusted net debt' to 'adjusted equity'. For this purpose, adjusted
net debt is defined as interest-bearing borrowings, less cash and cash equivalents. Adjusted equity comprises all
components of equity.

Other commitments:

The Company has entered into reagent agreement for a period ranging from 3 to 6 years with some of its major raw
material suppliers to purchase agreed value of raw materials.

The value of purchase commitments for the remaining number of years are ' 21,017.62 Lakhs (31 March 2025'20,068.20
Lakhs) of which annual commitment for next year is ' 6161.87 Lakhs (31 March 2025'4,761.88 Lakhs) as per the terms
of these arrangements.

The company has provided support to meet the payment of financial liabilities of its wholly owned subsidiary i.e DAPIC
Metropolis Healthcare Private Limited (Formerly known as Metropolis Histoxpert Digital Services Private Limited) and
Core Diagnostics Private Limited.

On 16 November 2022, the Income tax department conducted searches at premises of the Company and issued
assessment orders under Section 143(3) / 147 of the Income-Tax Act, 1961, ("Act") ("Order") for 10 years from AY 2014¬
15 to AY 2023-24 wherein they raised a demand of Rs. 7,306.46 lakhs. The Company filed rectification application against
the Orders for all 10 years out of which rectification orders for 7 AYs are received - the said rectifications are in line
with the requests filed by the Company and the demand stands reduced to Rs 3,880 Lakhs . Additionally, the Company
carries a a provision of Rs 1,964.04 lakhs in its accounts against this probable liability. The Company had separately
filed appeals before the Commissioner of Income Tax (Appeals) (CIT(A)) for all the above Assessment Years Thereafter,
the Company received appellate orders u/s 250 for the Income Tax Act for all the assessment years, wherein the CIT(A)
has allowed and accepted major grounds of appeal in favor of the Company. The Company has also received Income
Tax Refund of Rs. 1027.00 lakhs (net) in FY 2025-26 in respect of the above assessment years.

42 Leases1 The following is the summary of practical expedients elected on application:

i Applied a single discount rate to a portfolio of leases of similar assets in similar economic environment
with a similar end date.

ii Applied the exemption not to recognize right-of-use assets and liabilities for leases :

a. with less than 12 months of lease term on the date of initial application

b. Outflow of less than Rs. 5 Lakhs in entire tenure of arrangement

iii Excluded the initial direct costs from the measurement of the right-of-use asset at the date of
initial application.

iv Applied the practical expedient to grandfather the assessment of which transactions are leases on date
of transition. Accordingly, Ind AS 116 is applied only to contracts that were previously identified as leases
under Ind AS 17.

1 The effect of amortisation and interest related to Right Of Use Asset and Lease Liability are reflected in the
Statement of Profit and Loss under the heading "Depreciation and Amortisation Expense" and "Finance costs"
respectively under Notes 32 and 31

2 The incremental borrowing rate applied to lease liabilities for FY 25-26 is 8.91% -10.10% based on tenure of
arrangement

3 Following are the changes in the carrying value of right of use assets for the year ended 31 March, 2026:

8 The Company does not face a significant liquidity risk with regard to its lease liabilities as the current assets
are sufficient to meet the obligations related to lease liabilities as and when they fall due.

9 Rental expense recorded for short-term leases / Variable rent was Rs 13,881.81 Lakhs (31 March 2025 Rs Rs
11,798.19 Lakhs) for the year ended 31 March 2026.

10 The total cash outflow for leases for year ended 31 March 2026 is Rs 9,046.15 Lakhs (31 March 2025 Rs 8,450.97
Lakhs)

43(a) Revenue from contracts with customers

The Company generates its entire revenue from contracts with customers for the services at a point in time. The
Company is engaged mainly in the business of running laboratories for carrying out pathological investigations of
various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry,
immunology, virology, cytology, other pathological and radiological investigations, considered as a single source
of revenue.

(c) Employee Stock Option Schemes

Description of share-based payment arrangements:

As at 31 March 2026 and 31 March 2025 Company had following share-based payment arrangements:

RSU 2025-

This plan may be called the Metropolis-Restrictive Stock Units Plan, 2025 ("MHL - RSU Plan 2025"/"Plan") as
approved by the Board of Directors of the Company at its meeting held on May 13, 2025 as per the recommendation
of Nomination and Remuneration Committee and approved by members of the Company by passing special
resolution at the Annual General Meeting held on August 13, 2025.

This Plan shall be deemed to have come into force on August 13, 2025 (Being the date of passing of special
resolution for approving the MHL - RSU Plan 2025 by the shareholders of the Company).

RSU 2020 -

This plan may be called the Metropolis-Restrictive Stock Unit Plan, 2020 (MHL-RSU Plan, 2020) as approved by the Board
of Directors of the Company at its meeting held on February 6, 2020 as per the recommendation of Nomination and
Remuneration Committee and approved by members of the Company through postal ballot process on April 06, 2020.
This plan shall be deemed to have come into force on April 06, 2020 (being the date of passing of special resolutions
for approving the MHL-RSU Plan 2020 by the Shareholders of the Company through postal ballot process) or on
such date as may be decided by the Nomination and Remuneration Committee ("Committee") of the Company.

ESOP 2025 -

This plan may be called the Metropolis - Employees Stock Options Plan, 2025 ("MHL - ESOP Plan 2025"/Plan") as
approved by the Board of Directors of the Company at its meeting held on May 13,2025 as per the recommendation
of Nomination and Remuneration Committee and approved by members of the Company by passing special
resolution at the Annual General Meeting held on August 13, 2025.

This Plan shall be deemed to have come into force on August 13, 2025 (Being the date of passing of special
resolution for approving the MHL - ESOP Plan 2025 by the Shareholder of the Company).

MESOS 2015 -

The Company has instituted "Metropolis Employee Stock Option Plan 2015 "(MESOP 2015) for eligible employees.
In terms of the said plan, options to the employees shall vest at the rate of 30% of Grant on 36 months from Grant
Date, 35% of Grant on 48 months from Grant Date and 35% of Grant on 60 months from Grant Date. The vested
options can be exercised on earlier of Listing of Company Shares on an Indian Stock Exchange or 60 month from
the date of the grant. Further, option can only be exercised during the exercise window specified by the Company.
Each Option carries with it the right to purchase one equity share of the Company at the exercise price determined
by Nomination and Remuneration Committee.

There is no options outstanding as at 31 March 2026 (31 March 2025: Nil)

On 19 September 2017, consent was given by the Nomination and Remuneration Committee, wherein vesting
schedule was modified to grant options under Metropolis Employee Stock Options Scheme, 2015 (MESOS 2015).
As per modified terms, option to

- Existing employees (person who is in continuous employment with the Company since 1 January, 2016 or prior
thereto) shall vest at the rate of 50% of Grant on 1 January 2018, 25% of Grant on 1 January 2019 and 25% of
Grant on 1 January 2020.

- New employees (person who is in continuous employment with the Company after 01 January, 2016.) shall vest
at the rate of 50% of Grant on completion of 2 years from date of joining, 25% of Grant on completion of 3 years
from date of joining and 25% of Grant on completion of 4 years from date of joining.

- No additional options to be granted under MESOS 2015 as per the resolution dated 24 September 2018, passed
by the Nomination & Remuneration Committee

- Expected volatility of the option is based on historical volatility, during a period equivalent to the option life

- Dividend yield of the options is based on recent dividend activity

- Risk-free interest rates are based on the government securities yield in effect at the time of the grant.

(d) Compensatory absences:

The Company follows calendar year (January to December) for leave management. As per policy, Privilege Leave is
accrued on 1^st of January for the entire year. Leaves can be accumulated upto 30 days and can be encashed at the
time of exit along with full and final settlement. All other leaves get lapsed at the end of December.

46 Segment Reporting

Operating segments are defined as components of an enterprise for which discrete financial information is available
that is evaluated regularly by the chief operating decision maker, in deciding how to allocate resources and assess
performance. The Company's chief operating decision maker is the CEO of the Company.

Segment revenue, segment expenses, segment assets and segment liabilities have been identified to segments
on the basis of their relationship to the operating activities of the segment. Inter segment revenue is accounted on
the basis of transactions which are primarily determined based on market / fair value factors. Revenue, expenses,
assets and liabilities which relate to the Company as a whole and are not allocable to segments on a reasonable
basis have been included under "unallocated revenue / expenses / assets / liabilities".

Based on the nature of the business and line of products/ services, there is only one reportable segment - Pathology
service. Therefore there is no other reportable segment for the Company, in accordance with the requirements of
Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting Standard)
Rules, 2015.

47 Corporate social responsibility (CSR)

As per Section 135 of the Companies Act, 2013, a company, meeting the applicability threshold, needs to spend
at least 2% of its average net profit for the immediately preceding three financial years on corporate social
responsibility (CSR) activities. The areas for CSR activities is as per activities specified in Schedule VII of the
Companies Act, 2013.

(b) Deferred payment consideration

During the year ended 31 March 2026, the Company has entered into a business transfer agreement dated 7 August
2025 to acquire Ambika Pathology Laboratory located at Kolhapur, Maharashtra for an initial purchase consideration
of ' 1,700.00 lakhs, an amount of ' 1,530.00 lakhs is paid upfront by the Company to Dr. Rajendra Sadashiv Patil,
owner of Ambika Pathology Laboratory and the remaining 170.00 lakhs is to be paid at the end of thirty six months
from the date of acquisition as part of deferred consideration.

The deferred consideration of ' 170.00 Lakhs has been measured at fair value (' 131.00 Lakhs) on initial recognition
and the difference of ' 39.00 Lakhs will be recognised as finance cost on EIR basis over the payment tenure; During
year ended 31 March 2026, ' 6.43 lakhs (31 March 2025 ' Nil ) charged to statement of profit and loss (refer note 31).

During the year ended 31 March 2025, the Company had made an investment in Core Diagnostics Private Limited
for a total cash consideration of ' 13,576.08 Lakhs, of which ' 500 Lakhs was payable in June 2025. During the year
ended 31 March 2026, pursuant to closing diligence procedures and subsequent post-acquisition review, certain
matters requiring remediation and management intervention beyond those envisaged at the time of transaction
closure were identified. Accordingly, the aforesaid consideration payable of ' 500 Lakhs is no longer considered
payable and has therefore been written back in the Statement of Profit and Loss during the current year. (Refer
Note 5)

During the FY 19-20, Desai Metropolis Health Services Private Limited, a subsidiary of the Company, had entered
into a business purchase agreement to acquire Four Laboratories (Yash Lab, Nagar lab, Doctor Lab and Iyyer Lab)
located at Surat for an initial purchase consideration of ' 1,800.00 lakhs. The amount of ' 1,800.00 lakhs was to

49 Transfer Pricing

The Company's management is of the opinion that its international and domestic transactions are at arm's length
as per the independent firm's report for the year ended 31 March 2026. Management continues to believe that its
international transactions post 31 March 2025 and the specified domestic transactions are at arm's length and
that the transfer pricing legislation will not have any impact on these financial statements, particularly on amount
of tax expense and that of provision of taxation.

50 Shareholding in the subsidiary company:

Metropolis Healthcare Lanka Private Limited (Metropolis Lanka) has bought back 250,000 ordinary shares held by
Nawaloka Hospitals PLC ("Nawaloka") in Metropolis Lanka pursuant to memorandum of understanding (MOU) dated
31 March 2017. As per the MOU, the buy-back consideration payable by Metropolis Lanka was adjusted against
certain receivables payable by Nawaloka to Metropolis Lanka. As at 31 March 2026, Metropolis Lanka has not filed
relevant forms with Registrar of the Company in respect of share transfer. Currently, the shareholding records in
the books of Metropolis Lanka assumes that the buy-back has been effectuated as per the MOU and Metropolis
Healthcare Limited is reflected as 100% owner of Metropolis Lanka.

51 Disclosure of Transactions with Struck off companies

The Company did not have any material transactions with companies struck off under Section 248 of the Companies
Act, 2013 or Section 560 of Companies Act, 1956 during the financial year.

52 No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any
other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities
("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend
or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries). The Company has not received
any fund from any party (Funding Party) with the understanding that the Company shall whether, directly or indirectly
lend or invest in other persons or entities identified by or on behalf of the Company ("Ultimate Beneficiaries") or
provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

53 As at 31 March 2026, there are certain proceeds from exporting diagnostic services to its overseas subsidiaries
and certain other customers that have not been repatriated back into India within the stipulated timeframe as
prescribed by the Reserve Bank of India (RBI) Master Direction on reporting and realization of export proceeds,
including due to circumstances beyond the Company's control. The Company has duly applied to its Authorised
Dealer (AD) bank for an extension of time period to repatriate the outstanding export proceeds. The Company is
actively engaged with the AD bank to ensure compliance with RBI regulations and to facilitate the repatriation of
the export proceeds at the earliest. The Company does not consider any material impact in respect of the above
on the financial position or performance of the Company.

54 Events after reporting date

Where events occurring after the balance sheet date provide evidence of conditions that existed at the end of
the reporting period, the impact of such events is adjusted with the standalone financial statements. Otherwise,
events after the balance sheet date of material size or nature are only disclosed.

55 Business CombinationA Liquidation of Dr. Ganesan's Hitech Diagnostic Centre Private Limited

The Board of Directors of the Company, at their meeting held on 11 February 2022, accorded in-principle approval
for the voluntary liquidation of Dr. Ganesan's Hitech Diagnostic Centre Private Limited ('Hitech'), a wholly owned
subsidiary of the Company, to be carried out under the provisions of Insolvency and Bankruptcy Code, 2016. The
Board of Directors of Hitech in their meeting dated 01 April 2022 and the members of Hitech in their Extra Ordinary
General meeting held on 01 April 2022 have accorded their approval for consolidation of the business of Hitech
through voluntary liquidation process. Pursuant to the ongoing liquidation process, the liquidator of Hitech has
transferred the entire business undertaking to the Company on a going concern basis on and with effect from 04
June 2022.

On 18 April, 2024 the National Company Law Tribunal, Chennai Bench ("NCLT") has approved the dissolution of
Dr.Ganesan's Hitech Diagnostic Centre Private Limited ("Hitech", a wholly owned subsidiary of the Company) vide
its order. Pursuant to the Scheme becoming effective, Hitech ceased to be the subsidiary of the Company and got
merged with the Company. The entire business of Hitech was distributed to the Company on a going concern basis
on and with effect from 4 June 2022.

Also, accordingly, the Company gave effect of the liquidation as per the requirements of Appendix C to Ind AS
103 "Business Combination", to as if it had occurred from the beginning of the preceding period, being the date of
acquisition (i.e. 22 October 2021).

B Acquisition of subsidiaries

(i) On 21 March 2025, the Company has acquired 100% stake in Core Diagnostic Private Limited ("Core") for
the purchase consideration of Rs. 21,888.40 lakhs, discharged partly by cash consideration of Rs 13,576.08
lakhs and partly by way of preferential issue and allotment of 518,920 equity shares of Metropolis Healthcare
Limited amounting to Rs. 8,312.32 lakhs as per the terms and conditions of the Share Purchase Agreement
including amendments if any thereof entered between the Company and Core. Post completion of the aforesaid
acquisition, Core has become wholly owned subsidiary of the Company.

(ii) On 14 August 2024, the Company has acquired 100% stake in Metropolis Foundation (A section 8 Company
incorporated under Companies Act, 2013) for the purchase consideration of Rs. 0.10 lakh, discharged by cash
consideration of Rs 0.10 lakhs as per the terms and conditions of the Share Purchase Agreement including
amendments if any thereof entered between the Company and Metropolis Foundation. Post completion of the
aforesaid acquisition, it has become wholly owned subsidiary of the Company.

(iii) The Company incorporated Metropolis Clinical Pathology Private Limited (which subsequently changed its name
to Scientific Metropolis Pathology Private Limited) as its wholly owned subsidiary effective 25 December 2024.

(iv) The Company incorporated Metropolis Quality Solutions Private Limited as its wholly owned subsidiary effective
from 13 September 2025

C Acquisition of Business

During the year ended 31 March 2026, the Company has entered into a business transfer agreement dated 7 August
2025 to acquire Ambika Pathology Laboratory located at Kolhapur, Maharashtra for an initial purchase consideration
of ' 1,700.00 lakhs, an amount of ' 1,530.00 lakhs is paid upfront by the Company to Dr. Rajendra Sadashiv Patil,
owner of Ambika Pathology Laboratory and the remaining 170.00 lakhs is to be paid at the end of thirty six months
from the date of acquisition as part of deferred consideration.

56 Sale of EQAS division

During the current year, the Company entered into a Business Transfer Agreement ("BTA") with Metropolis Quality
Solutions Private Limited for the sale of its External Quality Assessment Scheme (EQAS) division for an aggregate
consideration of up to Rs. 125 Lakhs. The transaction was approved by the Board of Directors on 04 February 2026.

Accordingly, pursuant to the requirements of Ind AS 105, the operations relating to the said division have been
classified as discontinued operations and the related assets have been classified as assets held for sale in the
standalone financial statements. Consequently, the comparative standalone statement of profit and loss has been
re-presented to disclose the results of discontinued operations separately from continuing operations.

(c) Average inventory = (Opening inventory balance Closing inventory balance) / 2

(d) Net credit sales = Net credit sales consist of gross credit sales minus sales return

(e) Average trade receivables = (Opening trade receivables balance Closing trade receivables balance) / 2

(f) Net credit purchases = Net credit purchases consist of gross credit purchases minus purchase return

(g) Average trade payables = (Opening trade payables balance Closing trade payables balance) / 2

(h) Working capital = Current assets - Current liabilities.

(i) Earning before interest and taxes = Profit before exceptional items and tax Finance costs - Other Income

(j) Capital Employed = Tangible Net Worth Total Debt Deferred Tax Liability

58 No transactions to report against the following disclosure requirements as notified by MCA pursuant to amended
Schedule III:

(a) Crypto Currency or Virtual Currency

(b) Benami Property held under Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder

(c) Registration of charges or satisfaction with Registrar of Companies

(d) Relating to borrowed funds:

i. Wilful defaulter

ii. Utilisation of borrowed funds and securities premium

iii. Borrowings obtained on the basis of security of current assets

iv. Discrepancy in utilisation of borrowings

v. Current maturity of long term borrowings

(e) Number of layers of companies as prescribed under clause section 87(2) of the Companies Act, 2013